PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, BIOMARKERS, & EFFICACY OF TOMINERSEN IN INDIVIDUALS WITH PRODROMAL & EARLY MANIFEST HUNTINGTON'S DISEASE

  • Lie, Yenni (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA/ERM Reference Number: 95061
Monash Health Reference: RES-23-0000-431X
SSA Reference Number: SSA/95061/MonH-2023-386141(v2)
StatusActive
Effective start/end date27/07/23 → 26/07/28